Pharmacological evaluation of novel 5-HT(3) receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery

OBJECTIVE: In the last few decades, serotonin type-3 (5-HT(3)) receptor antagonists have been identified as potential targets for anxiety disorders. In preclinical studies, 5-HT(3) antagonists have shown promising antianxiety effects. In this study, a novel 5-HT(3) receptor antagonist, QCM-13(N-cycl...

Descripción completa

Detalles Bibliográficos
Autores principales: Gupta, Deepali, Radhakrishnan, Mahesh, Thangaraj, Devadoss, Kurhe, Yeshwant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399007/
https://www.ncbi.nlm.nih.gov/pubmed/25883513
http://dx.doi.org/10.4103/0975-7406.154429

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4399007/
https://www.ncbi.nlm.nih.gov/pubmed/25883513
http://dx.doi.org/10.4103/0975-7406.154429

Ejemplares similares